Scarica l'app Stockscreener
15.61
0.90%
0.14
Dopo l'orario di chiusura:
15.63
0.02
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.47
Aprire:
$15.2
Volume 24 ore:
1.26M
Relative Volume:
1.22
Capitalizzazione di mercato:
$2.08B
Reddito:
$283.06M
Utile/perdita netta:
$287.20M
Rapporto P/E:
7.5153
EPS:
2.0771
Flusso di cassa netto:
$135.69M
1 W Prestazione:
+6.92%
1M Prestazione:
+9.85%
6M Prestazione:
+38.63%
1 anno Prestazione:
+90.60%
Intervallo 1D:
$15.05
$15.69
Intervallo di 1 settimana:
$13.81
$15.69
Portata 52W:
$6.825
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.61 | 2.08B | 283.06M | 287.20M | 135.69M | 2.0771 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - msn.com
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
Why Aurinia Pharmaceuticals stock is surging Monday morning - msn.com
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia to Acquire Kezar via $6.955-Per-Share Cash Tender Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
How Aurinia Pharmaceuticals Inc (AUPH) Affects Rotational Strategy Timing - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (AUP.TO) Competitors - Meyka
Aurinia Pharmaceuticals (AUPH) COO Ryan Cole becomes SEC Form 3 insider - Stock Titan
Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3 - Stock Titan
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
JPMorgan Chase & Co. Grows Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
EBIT per share of Aurinia Pharmaceuticals Inc. – LSE:0UJF - TradingView
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - MarketScreener
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - TipRanks
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - Stock Titan
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors - Sahm
Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)? - finance.yahoo.com
Investors - Aurinia Pharmaceuticals Inc.
Mutiny at Aurinia Pharmaceuticals? Biotech rallies on C-suite shake-up - MSN
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance (NASDAQ:AUPH) - Seeking Alpha
AUPH Should I Buy - Intellectia AI
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study - ChartMill
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround - Stocktwits
AURINIA PHARMACEUTICALS PB Ratio: 3.29 — 11% Below Median - GuruFocus
The Escalator: Aurinia Pharmaceuticals, Abivax, Ogilvy Health and more - Medical Marketing and Media
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets - MSN
[SCHEDULE 13D/A] Aurinia Pharmaceuticals Inc. Amended Major Shareholder Report - Stock Titan
AUPH SEC FilingsAurinia Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Aurinia Resets Leadership And Capital Plans As Valuation Gap Persists - Sahm
Aurinia names board chair Kevin Tang as new CEO By Investing.com - Investing.com Canada
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up - Investor's Business Daily
Aurinia appoints Kevin Tang as CEO with zero compensation By Investing.com - Investing.com India
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):